-
Reactive oxygen species regulate early development of the intestinal macrophage-microbiome interface. Blood (IF 21.0) Pub Date : 2025-02-03 Zohreh Mansoori Moghadam,Bei Zhao,Candice Raynaud,Valentina Strohmeier,Jana Neuber,Anne Kathrin Lösslein,Sabrina Qureshi,Vitka Gres,Tara Ziegelbauer,Sebastian Baasch,Christoph Schell,Klaus Warnatz,Naohiro Inohara,Gabriel Nunez,Thomas Clavel,Stephan Patrick Rosshart,Julia Kolter,Philipp Henneke
Controlled development of cellular intestinal immunity in the face of dynamic microbiota emergence constitutes a major challenge in very early life, and a bottleneck for sustained growth and well-being. Early-onset inflammatory bowel disease (IBD) represents an extreme disturbance of intestinal immunity. It is a hallmark, and often the first manifestation of chronic granulomatous disease (CGD), caused
-
Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD. Blood (IF 21.0) Pub Date : 2025-02-03 Michael C Zaiken,Sujeong Jin,Cameron McDonald-Hyman,Christina Hartigan,Peter Sage,Keli L Hippen,Brent H Koehn,Angela Panoskaltsis-Mortari,Megan J Riddle,Cindy Eide,Jakub Tolar,Geoffrey R Hill,Leo Luznik,Corey S Cutler,Jerome Ritz,Leslie S Kean,Ageliki Tsagaratou,Anjana Rao,Bruce R Blazar
Chronic graft-versus-host disease (cGVHD) is the leading cause of morbidity and non-relapse associated mortality following allogeneic hematopoietic cell transplantation (aHSCT). Treating steroid resistant/refractory cGVHD remains challenging. Epigenetic regulators can have global transcriptional effects that control donor T-cell responses. We previously showed that inhibiting histone lysine motifs
-
How I approach pharmacological thromboprophylaxis in children. Blood (IF 21.0) Pub Date : 2025-02-03 Anthony A Sochet,Amy Kiskaddon,Neil A Goldenberg
The incidence of venous thromboembolism in children continues to rise, with the most recent analysis from the Pediatric Hospital Information Systems database in the United States reporting a 200-fold increase in pediatric hospitalization-related venous thromboembolism diagnoses over the past two decades. In the past decade, several pediatric venous thromboembolism risk prediction models have been published
-
IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy. Blood (IF 21.0) Pub Date : 2025-02-03 Marcos Garcia-Lacarte,Sara C Grijalba,Javier Melchor Sánchez,Marien Pascual,Enrique Goni,Inigo Clemente-Larramendi,Sandra Morales-Sanchez,Maria A Burrell,Oscar Blanco,Adrian Arnaiz-Leché,Blanca S Berrozpe,Maria Amann,Christian Klein,Pablo Umaña,Miguel Angel Canales,Jose Angel Martinez-Climent,Juan Jose Lasarte,Pablo Sarobe,Francisco J Novo,Sergio Roa
The contribution of IL-10 secreted by tumoral B cells to the progression and shaping of the microenvironment in diffuse large B-cell lymphoma (DLBCL) with activated B-cell (ABC) phenotype is not yet completely understood. To shed light on this issue, we generated an immunocompetent mouse model of ABC-DLBCL with conditional knock-out of IL-10 specifically in malignant B cells. Paradoxically, these mice
-
MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial. Blood (IF 21.0) Pub Date : 2025-01-30 Moritz Fürstenau,Sandra Robrecht,Christof Schneider,Eugen Tausch,Adam Giza,Matthias Ritgen,Jörg T Bittenbring,Holger Hebart,Björn Schöttker,Anna Lena Lena Illert,Ullrich Graeven,Andrea Stoltefuss,Bernhard Heinrich,Robert Eckert,Anna-Maria Fink,Janina Stumpf,Kirsten Fischer,Othman Al-Sawaf,Florian Simon,Fanni Kleinert,Jonathan Weiss,Karl-Anton Kreuzer,Anke Schilhabel,Monika Brüggemann,Petra Langerbeins
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were enrolled and two patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of one prior therapy
-
-
For how long has this problem been there? Blood (IF 21.0) Pub Date : 2025-01-30 Niccolò Bolli,Matteo Claudio da Vià
-
Targeting CD47: many misses; hopeful for a hit. Blood (IF 21.0) Pub Date : 2025-01-30 Lindsay Wilde,Margaret Kasner
-
-
A 3-pronged attack on TP53-mutated MCL. Blood (IF 21.0) Pub Date : 2025-01-30 Christine E Ryan,Ann S LaCasce
-
c-MYC stain as a potential minimal residual disease marker for acute myeloid leukemia with NPM1 mutation. Blood (IF 21.0) Pub Date : 2025-01-30 Kirill A Lyapichev,Amir Behdad
-
-
How to prioritize between oxygen and iron. Blood (IF 21.0) Pub Date : 2025-01-30 Esther G Meyron-Holtz
-
Sickle Cell Trait Does Not Cause "Sickle Cell Crisis" Leading to Exertion-Related Death: A Systematic Review. Blood (IF 21.0) Pub Date : 2025-01-30 Lachelle D Weeks,Allecia M Wilson,Rakhi P Naik,Yvonne A Efebera,Mohammad Hassan Murad,Anjlee Mahajan,Patrick T McGann,Madeleine Verhovsek,Angela C Weyand,Ahmar Urooj Zaidi,Michael R DeBaun,Chancellor Donald,Roger A Mitchell
Globally, an estimated 300 million individuals have sickle cell trait (SCT), the carrier state for sickle cell disease. While sickle cell disease (SCD) is associated with increased morbidity and shortened lifespan, SCT has a lifespan comparable to that of the general population. However, "sickle cell crisis" has been used as a cause of death for decedents with SCT in reports of exertion-related death
-
Xu H, Cao Y, Yang X, Cai P, Kang L, Zhu X, Luo H, Lu L, Wei L, Bai X, Zhu Y, Zhao B-Q, Fan W. ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery. Blood. 2017;130(1):11-22. Blood (IF 21.0) Pub Date : 2025-01-30 Production Staff
This article has been retracted; please see Elsevier's Article Correction, Retraction and Removal Policy (Article withdrawal | Elsevier policy).This article has been retracted at the request of the Editors.Within the paper, image duplications were identified in Figures 2 and 6 and supplemental Figure 4. Image duplications were also identified between Figure 1 and supplemental Figure 4 from this paper
-
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood (IF 21.0) Pub Date : 2025-01-27 Sravya Tumuluru,James K Godfrey,Alan Cooper,Jovian Yu,Xiufen Chen,Brendan MacNabb,Girish Venkataraman,Yuanyuan Zha,Benedikt Pelzer,Joo Y Song,Gerben Duns,Brian Sworder,Sandeep S Raj,Christopher R Bolen,Elicia Penuel,Ekaterina Postovalova,Nikita Kotlov,Aleksander Bagaev,Nathan H Fowler,Roni Shouval,Sonali M Smith,Ash A Alizadeh,Christian Steidl,Justin P Kline
Most diffuse large B-cell lymphoma (DLBCL) patients treated with immunotherapies such as bispecific antibodies (BsAb) or chimeric antigen receptor (CAR) T cells fail to achieve durable treatment responses, underscoring the need for a deeper understanding of mechanisms that regulate the immune environment and response to treatment. Here, an integrative, multi-omic approach was applied to multiple large
-
Frontline treatment of follicular lymphoma: What will it take to change current practice? Blood (IF 21.0) Pub Date : 2025-01-27 Emmanuel Bachy,Kim Linton
Follicular lymphoma is the most common subtype of indolent lymphoma. Despite multiple trials over the past decade showing improved progression-free survival with new first-line therapeutic strategies -such as anti-CD20 maintenance therapy and new glycoengineered anti-CD20 antibodies- no standardized approach has been widely adopted in routine clinical practice. Several factors may explain this, including
-
IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput drug screening. Blood (IF 21.0) Pub Date : 2025-01-27 Marcel F Pohly,Kerstin Putzker,Sebastian Scheinost,Lena Ben Taarit,Tatjana Walther,Sandra Kummer,Tobias Wertheimer,Minqi Lin,Thi Huong Lan Do,Kristina Handler,Jan Michler,Jarno Kivioja,Karsten Bach,Samanta Kisele,James Kim,Sascha Dietrich,Beat Bornhauser,Wendy Wei-Lynn Wong,Burkhard Becher,Andreas Moor,Joe David Lewis,Xenia Maria Ficht,Junyan Lu,Wolfgang Huber,Thorsten Zenz
T-cell prolymphocytic leukemia (T-PLL) is an aggressive lymphoid malignancy with limited treatment options. To discover new treatment targets for T-PLL, we performed high-throughput drug sensitivity screening on 30 primary patient samples ex-vivo. After screening over 2'800 unique compounds, we found T-PLL to be more resistant to most drug classes, including chemotherapeutics, compared to other blood
-
Platelet activation and signaling in thrombus formation. Blood (IF 21.0) Pub Date : 2025-01-27 Frauke Swieringa,Johan W M Heemskerk,Alice Assinger
In thrombosis and hemostasis, the formation of a platelet-fibrin thrombus or clot is a highly controlled process that varies, depending on the pathological context. Major signaling pathways in platelets are well established. However, studies with genetically modified mice have identified the contribution of hundreds of additional platelet-expressed proteins in arterial thrombus formation and bleeding
-
Advances in RNA editing in hematopoiesis and associated malignancies. Blood (IF 21.0) Pub Date : 2025-01-27 Shuangshuang Pu,Tao Cheng,Hui Cheng
Adenosine-to-inosine (A-to-I) RNA editing is a prevalent RNA modification essential for cell survival. The process is catalyzed by the Adenosine Deaminase Acting on RNA (ADAR) enzyme family that converts adenosines in double-stranded RNAs (dsRNAs) into inosines, which are read as guanosines during translation. Deep sequencing has helped to reveal that A-to-I editing occurs across various types of RNAs
-
Factor XIII: Driving (Cross-)Links in Hemostasis, Thrombosis, and Disease. Blood (IF 21.0) Pub Date : 2025-01-27 James P Luyendyk,Matthew J Flick,Alisa S Wolberg
Blood clots are complex structures composed of blood cells and proteins held together by the structural framework provided by an insoluble fibrin network. Factor (F)XIII is a protransglutaminase essential for stabilizing the fibrin network. Activated FXIII(a) introduces novel covalent crosslinks within and between fibrin and other plasma and cellular proteins, and thereby promotes fibrin biochemical
-
Babesiosis and Sickle Red blood Cells: Loss of Deformability, Heightened Osmotic fragility, and Hypervesiculation. Blood (IF 21.0) Pub Date : 2025-01-27 Divya Beri,Marilis A Rodriguez,Manpreet Singh,Daniel McLaughlin,Yunfeng Liu,Hui Zhong,Avital Mendelson,Xiuli An,Deepa G Manwani,Karina Yazdanbakhsh,Cheryl A Lobo
Babesiosis in sickle cell disease (SCD) is marked by severe anemia but the underlying red blood cell (RBC) rheological parameters remain largely undefined. Here, we describe altered RBC deformability from both primary (host RBC sickle hemoglobin mediated) and secondary changes (Babesia parasite infection mediated) to the RBC membrane using wild type AA, sickle trait AS and sickle SS RBCs. Our ektacytometry
-
DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis. Blood (IF 21.0) Pub Date : 2025-01-24 Sebastiaan N J Laan,Jessica Del Castillo,Suzanne C Cannegieter,Karin Fijnvandraat,Marieke J H A Kruip,Saskia le Cessie,Ruben Bierings,Jeroen C J Eikenboom,Iris van Moort
Desmopressin (DDAVP) can be used to prevent or stop bleeding. However, large inter-individual variability is observed in DDAVP response and determinants are largely unknown. In this systematic review and meta-analysis we aim to identify the response to DDAVP, and the factors that determine DDAVP response in patients. We included studies with patients with any bleeding disorder receiving DDAVP. First
-
The Fit Older Adult with Acute Myeloid Leukemia: Clinical Challenges to Providing Evidence-Based Frontline Treatment. Blood (IF 21.0) Pub Date : 2025-01-24 Sameem M Abedin,Geoffrey L Uy,Laura C Michaelis
Recent advances in acute myeloid leukemia (AML) come from studies investigating younger (age<60 years) adults or older (age≥75 years) or less fit adults. Uncertainty exists for the management of otherwise healthy adults with AML in their 60s and 70s, which also represents a significant proportion of AML cases. We discuss current considerations in older, fit adults with AML including determination of
-
One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying them. Blood (IF 21.0) Pub Date : 2025-01-24 Ainsley V C Knox,Lauren Y Cominsky,Di Sun,Emylette Cruz Cabrera,Brian E Nolan,Edann Ofray,Elisa Benetti,Camilla Visconti,Federica Barzaghi,Sergio D Rosenzweig,Monica Ghei Lawrence,Kathleen E Sullivan,Samuel Yoon,Suzanna Rachimi,Nurcicek Padem,Erin Conboy,Maja Stojanovic,Gordana Petrovic,Srdjan Pasic,Joseph A Church,Ronald M Ferdman,Fabio Candotti,Tiphaine Arlabosse,Katerina Theodoropoulou,Cullen M
Leukopoiesis is lethally arrested in mice lacking the master transcriptional regulator PU.1. Depending on the animal model, subtotal PU.1 loss either induces acute myeloid leukemia or arrests early B cell and dendritic cell development. Although humans with absolute PU.1 deficiency have not been reported, a small cadre of congenital agammaglobulinemia patients with sporadic, inborn PU.1 haploinsufficiency
-
-
-
-
“Complementing” hemolytic anemias: what’s next? Blood (IF 21.0) Pub Date : 2025-01-23 Eleni Gavriilaki, Gloria F. Gerber
-
-
CD5-positive high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements Blood (IF 21.0) Pub Date : 2025-01-23 Wei J. Wang, Zhihong Hu
-
-
-
Introduction to a How I Treat series on iron overload in hematologic disorders Blood (IF 21.0) Pub Date : 2025-01-23 Thomas D. Coates
-
-
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial. Blood (IF 21.0) Pub Date : 2025-01-22 Aurore Perrot,Cyrille Touzeau,Jerome Lambert,Cyrille Hulin,Denis Caillot,Lionel Karlin,Bertrand Arnulf,Philippe Rey,Laurent Garderet,Margaret Macro,Martine Escoffre-Barbe,Julie Gay,Thomas Chalopin,Romain Gounot,Jean Marc Schiano de Colella,Mourad Tiab,Mohamad Mohty,Frédérique Kuhnowski,Jean Fontan,Salomon Manier,Frederique Orsini Piocelle,Laure Vincent,Sophie Rigaudeau,Xavier Leleu,Benjamin Hébraud
In patients with transplant-eligible newly diagnosed multiple myeloma, induction therapy with a quadruplet regimen prior to autologous transplant is the standard of care. The phase III IFM2020-02-MIDAS study (NCT04934475) assessed a minimal residual disease (MRD)-driven consolidation and maintenance strategy following induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD)
-
Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel CRBN-binding agents in myeloma. Blood (IF 21.0) Pub Date : 2025-01-22 Yakinthi Chrisochoidou,Andrea Scarpino,Salomon Morales,Shannon Martin,Sarah Anne Bird,Yigen Li,Brian A Walker,John Caldwell,Yann-Vai Le Bihan,Charlotte Pawlyn
Immunomodulatory drug (IMiD) resistance is a key clinical challenge in myeloma treatment. Previous data suggests almost one third of myeloma patients acquire mutations in the key IMiD effector cereblon by the time they are pomalidomide refractory. Some events, including stop codons/frameshift mutations and copy loss, having clearly explicable effects on cereblon function. Missense mutations have also
-
Dual Biological Role and Clinical Impact of De Novo Chromatin Activation in Chronic Lymphocytic Leukemia. Blood (IF 21.0) Pub Date : 2025-01-22 Vicente Chapaprieta,Alba Maiques-Diaz,Ferran Nadeu,Guillem Clot,Ramon Massoni-Badosa,Pablo Mozas,Judith Mateos-Jaimez,Anna Vidal Crespo,Stella Charalampopoulou,Martí Duran-Ferrer,Romina Royo,Núria Russiñol,Laura Llaó Cid,Juan A Piñeyroa,Neus Villamor,Holger Heyn,Sophie A Herbst,Junyan Lu,Dean J Bryant,Jonathan C C Strefford,Sascha Dietrich,Thorsten Zenz,Julio Delgado,Armando López-Guillermo,Elías Campo
Previous studies have reported that chronic lymphocytic leukemia (CLL) shows a de novo chromatin activation pattern as compared to normal B cells. Here, we explored whether the level of chromatin activation is related to the clinical behavior of CLL. We identified that in some regulatory regions, increased de novo chromatin activation is linked to clinical progression whereas, in other regions, it
-
HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA. Blood (IF 21.0) Pub Date : 2025-01-22 Ana Carolina Caballero Gonzalez,Cristina Ujaldón-Miró,Paula Pujol-Fernández,Rosanna Montserrat-Torres,Maria Guardiola-Perello,Eva Escudero-López,Irene Garcia-Cadenas,Albert Esquirol,Rodrigo Martino,Paola Jara-Bustamante,Pol Ezquerra Condeminas,Jose Manuel Soria,Eva Iranzo Ribera,Maria-Estela Moreno-Martinez,Mireia Riba,Jorge Sierra,Carmen Alvarez-Fernández,Laura Escribà-Garcia,Javier Briones
CD30-directed CART cell therapy (CART30) has limited efficacy in relapsed or refractory patients with CD30+ lymphoma, with a low proportion of durable responses. We have developed an academic CART30 cell product (HSP-CAR30) by combining strategies to improve performance. HSP-CAR30 targets a proximal epitope within the non-soluble part of CD30, and the manufacturing process includes a modulation of
-
GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia. Blood (IF 21.0) Pub Date : 2025-01-22 Fatemeh Alikarami,Hongbo M Xie,Simone S Riedel,Haley Goodrow,Declan Raymond Barrett,Leila Mahdavi,Alexandra Lenard,Changya Chen,Taylor Yamauchi,Etienne Danis,Zhendong Cao,Vu Le-Huy Tran,Mabel Minji Jung,Yapeng Li,Hua Huang,Junwei Shi,Kai Tan,David Trent Teachey,Emery H Bresnick,Tobias Neff,Kathrin Maria Bernt
Stemness-associated cell states are linked to chemotherapy resistance in AML. We uncovered a direct mechanistic link between expression of the stem cell transcription factor GATA2 and drug resistance. The GATA-binding protein 2 (GATA2) plays a central role in blood stem cell generation and maintenance. We find substantial intra- and inter-patient variability in GATA2 expression across AML patient samples
-
NETs persisting in vasculature undergo self-renewal with consequences for subsequent infection: a mouse model study. Blood (IF 21.0) Pub Date : 2025-01-22 Michal Santocki,Anna Such,Dominika Drab,Gabriela Burczyk,Elzbieta Kolaczkowska
While key for pathogen immobilization, neutrophil extracellular traps (NETs) often cause severe bystander cell/tissue damage. This was hypothesized to depend on their prolonged presence in the vasculature, leading to cytotoxicity. Imaging of NETs (histones, neutrophil elastase, extracellular DNA) with intravital microscopy in blood vessels of mouse livers in a pathogen-replicative-free environment
-
Aging platelets shift their hemostatic properties to inflammatory functions. Blood (IF 21.0) Pub Date : 2025-01-22 Afra Anjum,Magdalena Mader,Shaan Mahameed,Abhinaya Muraly,Frederik Denorme,Fabian P Kliem,Dario Rossaro,Sezer Akgöl,Lea Di Fina,Maité Mulkers,Lisa Sophia Laun,Lukas Li,Nadja Kupper,Keyang Yue,Marie-Louise Hoffknecht,Anastassia Akhalkatsi,Quentin Loew,Joachim Pircher,Raphael Escaig,Erwin F Strasser,Christian Wichmann,Kami Pekayvaz,Bernhard Nieswandt,Christian Schulz,Maria S Robles,Rainer Kaiser,Steffen
Platelets are crucial players in hemostasis and thrombosis, but also contribute to immune regulation and host defense, using different receptors, signaling pathways and effector functions, respectively. Whether distinct subsets of platelets specialize in these diverse tasks is insufficiently understood. Here, we employed an in vivo pulse-labelling method in Mus musculus models for tracking in vivo
-
Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis. Blood (IF 21.0) Pub Date : 2025-01-22 Christine Van Laer,Renaud Lavend'homme,Sarissa Baert,Koenraad De Wispelaere,Chantal Thys,Cyrielle Kint,Sam Noppen,Kathelijne Peerlinck,Chris Van Geet,Dominique Schols,Thomas Vanassche,Veerle Labarque,Peter Verhamme,Marc G Jacquemin,Kathleen Freson
Thrombomodulin (TM) expressed on endothelial cells regulates coagulation. Specific nonsense variants in the TM gene, THBD, result in high soluble TM levels causing rare bleeding disorder. In contrast, though THBD variants have been associated with venous thromboembolism, this association remains controversial. A multigene panel was used to diagnose 601 patients with inherited bleeding or thrombotic
-
CD44-Mediated Metabolic Rewiring is A Targetable Dependency of IDH-Mutant Leukemia. Blood (IF 21.0) Pub Date : 2025-01-22 Junhua Lyu,Yuxuan Liu,Ningning Liu,Hieu Vu,Feng Cai,Hui Cao,Pranita Kaphle,Zheng Wu,Giovanni A Botten,Yuannyu Zhang,Jin Wang,Sarada Achyutuni,Xiaofei Gao,Ilaria Iacobucci,Charles G Mullighan,Stephen S Chung,Min Ni,Ralph J DeBerardinis,Jian Xu
Recurrent IDH mutations catalyze NADPH-dependent production of oncometabolite R-2HG for tumorigenesis. IDH inhibition provides clinical response in a subset of acute myeloid leukemia (AML) cases; however, most patients develop resistance, highlighting the need for more effective IDH-targeting therapies. By comparing transcriptomic alterations in isogenic leukemia cells harboring CRISPR base-edited
-
IL-1R1 and IL-18 Signals Regulate Mesenchymal Stromal Cells in an Aged Murine Model of Myelodysplastic Syndromes. Blood (IF 21.0) Pub Date : 2025-01-22 Yuko Kawano,Hiroki Kawano,Mark W LaMere,Elizabeth A LaMere,Daniel K Byun,Kathleen McGrath,James Palis,Jeevisha Bajaj,Jane L Liesveld,Yoshio Katayama,Satoshi Yamazaki,Reuben Kapur,Laura M Calvi,Tzu-Chieh Ho,Michael W Becker
Myelodysplastic syndromes (MDS) are age-related diseases characterized by bone marrow (BM) dysfunction and an increased risk of developing acute leukemia. While there is growing evidence highlighting the crucial role of the BM microenvironment (BMME) in MDS, the specific influence of inflammation on BMME changes, as well as the potential benefits of targeting cytokines therapeutically, remain to be
-
CpG island methylator phenotype classification improves risk assessment in pediatric T-cell Acute Lymphoblastic Leukemia. Blood (IF 21.0) Pub Date : 2025-01-22 Fernanda Schäfer Hackenhaar,Nina Refhagen,Melanie M Hagleitner,Frank N van Leeuwen,Hanne Vibeke Marquart,Hans Ole Madsen,Mattias Landfors,Pia Osterman,Kjeld Schmiegelow,Trond Flaegstad,Olafur G Jonsson,Jukka Kanerva,Jonas Abrahamsson,Mats Heyman,Ulrika Noren-Nystrom,Magnus Hultdin,Sofie Degerman
Current intensive treatment of pediatric T-cell acute lymphoblastic leukemia (T-ALL) has substantial side-effects, highlighting a need for novel biomarkers to improve risk stratification. Canonical biomarkers such as genetics and immunophenotype are largely not used in pediatric T-ALL stratification. This study aimed to validate the prognostic relevance of DNA methylation CpG island methylator phenotype
-
Two-layered immune escape in AML is overcome by Fcγ receptor activation and inhibition of PGE2 signaling in NK cells. Blood (IF 21.0) Pub Date : 2025-01-21 Charlotte Rothfuß,Tobias Baumann,Sainitin Donakonda,Bettina Brauchle,Anetta Marcinek,Christian Urban,Julia Mergner,Anna-Marie Pedde,Anna Hirschberger,Christina Krupka,Anne-Sophie Neumann,Gerulf Hänel,Camilla Merten,Rupert Öllinger,Judith S Hecker,Tanja Bauer,Christian Rudolf Schmid,Katharina S Götze,Jennifer Altomonte,Veit L Bücklein,Roland Jacobs,Roland Rad,Corinna Dawid,Luca Simeoni,Burkhart Schraven
Loss of anticancer NK cell function in AML patients is associated with fatal disease progression and remains poorly understood. Here, we demonstrate that AML-blasts isolated from patients rapidly inhibit NK cell function and escape NK cell-mediated killing. Transcriptome analysis of NK cells exposed to AML-blasts revealed increased CREM expression and transcriptional activity, indicating enhanced cAMP
-
Is it time to screen for multiple myeloma? Blood (IF 21.0) Pub Date : 2025-01-16 Irene M Ghobrial,Floris Chabrun
-
B-1 B cells lose self-control in SCD. Blood (IF 21.0) Pub Date : 2025-01-16 David R Gibb,Sean R Stowell
-
HLA-I aberrations in cutaneous T-cell lymphoma. Blood (IF 21.0) Pub Date : 2025-01-16 Ting Zhou,Kojo S J Elenitoba-Johnson
-
Combined targeted modality in cHL: a risky bet? Blood (IF 21.0) Pub Date : 2025-01-16 Paul J Bröckelmann,Bastian von Tresckow
-
-
Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia Blood (IF 21.0) Pub Date : 2025-01-16 Julian Ronnacker, Michael Grau, Maximilian Klasmeier, Christian Klesse, Henning Baldauf, Stefan Abert, Andrew F. Berdel, Friederike T. Füsser, Sarah Sandmann, Jörn Albring, Christian Reicherts, Simon Call, Julia Marx, Matthias Floeth, Eva Eßeling, Lina Kolloch, Philipp Berning, Annika Scheller, Klaus Wethmar, Hartmut Schmidt, Bernhard Schluter, Wolfgang E. Berdel, Benjamin N. Ostendorf, Sohail F. Tavazoie
Apolipoprotein E (APOE) has multiple functions in metabolism and immunoregulation. Its common germ line variants APOE2, APOE3, and APOE4 give rise to 3 functionally distinct gene products. Previous studies reported yin-yang roles of APOE2 and APOE4 in immunological processes, but their effects in hematopoietic stem cell transplantation (HSCT) have never been studied. We performed APOE genotyping in
-
Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype Blood (IF 21.0) Pub Date : 2025-01-16 Pallavi Galera, Deepika Dilip, Andriy Derkach, Alexander Chan, Yanming Zhang, Sonali Persuad, Tanmay Mishra, Kyle Kramer, Mahak Kathpalia, Ying Liu, Christopher Famulare, Qi Gao, Douglas A. Mata, Maria Arcila, Mark B. Geyer, Eytan Stein, Ahmet Dogan, Mikhail Roshal, Ross L. Levine, Jacob Glass, Wenbin Xiao
A mixed phenotype (MP) is a characteristic of de novo MP acute leukemia (MPAL), but it can also be found in other leukemias. It poses substantial classification and management dilemmas. Herein, we report a large cohort of acute leukemia with MP and define acute myeloid leukemia with MP (AML-MP) and MPAL as 2 distinct groups by characterizing clinical, genetic, and transcriptomic features. Clinically
-
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma Blood (IF 21.0) Pub Date : 2025-01-16 Wenjuan Yu, Ping Li, Lili Zhou, Min Yang, Shiguang Ye, Dan Zhu, Jiaqi Huang, Xin Yao, Yan Zhang, Lanfang Li, Jing Zhao, Kevin Zhu, Jing Li, Chengxiao Zheng, Liping Lan, Hui Wan, Yihong Yao, Huilai Zhang, Daobin Zhou, Jie Jin, Aibin Liang
Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor T cell, targets and eliminates CD19/CD20-positive tumor cells. This phase 1, open-label study investigated the safety and efficacy of prizlon-cel in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). Patients with CD19 and/or CD20-positive R/R B-NHL received a 3-day lymphodepletion (cyclophosphamide:
-
How I diagnose and treat systemic mastocytosis with an associated hematologic neoplasm Blood (IF 21.0) Pub Date : 2025-01-16 Deepti H. Radia
Over the last decade significant advances have been made by honing the diagnostic evaluation and the significance of molecular profiles in patients with nonadvanced and advanced systemic mastocytosis (AdvSM). This is reflected in the 2022 iterations of the World Health Organization edition 5 and International Consensus Criteria classifications. The impact of targeted KIT inhibitor therapies on patients
-
Development of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosis Blood (IF 21.0) Pub Date : 2025-01-16 Emily Baumrin, Joseph Pidala, Sandra A. Mitchell, Lynn Onstad, Stephanie J. Lee
Sclerosis is a highly morbid manifestation of chronic graft-versus-host disease (cGVHD), associated with distressing symptoms and significant long-term disability. A patient-reported outcome (PRO) measure for cGVHD-associated sclerosis is essential to advance therapeutic trials. We aimed to develop a PRO for adults with cGVHD-associated sclerosis and evaluate and refine its content validity. Adults
-
Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements Blood (IF 21.0) Pub Date : 2025-01-16 Grace Egan, Sarah K. Tasian
Robust genetic characterization of pediatric acute myeloid leukemia (AML) has demonstrated that fusion oncogenes are highly prevalent drivers of AML leukemogenesis in young children. Identification of fusion oncogenes associated with adverse outcomes has facilitated risk stratification of patients, although successful development of precision medicine approaches for most fusion-driven AML subtypes
-
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial Blood (IF 21.0) Pub Date : 2025-01-16 Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, Marc S. Raab, Sandra Sauer, Maximilian Merz, Elias Karl Mai, Carsten Müller-Tidow, Steffen Luntz, Anna Jauch, Peter Brossart, Martin Goerner, Stefan Klein, Bertram Glass, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Ivana von Metzler, Hans W. Lindemann, Christof Scheid, Igor-Wolfgang Blau, Hans J. Salwender, Richard Noppeney, Britta
The multicenter, phase 3 German Myeloma Multicenter Group (GMMG) ReLApsE trial randomized patients with relapsed and/or refractory multiple myeloma (RRMM) equally to lenalidomide/dexamethasone (LEN/DEX; 25 mg days 1-21/40 mg weekly, in 4-week cycles) reinduction, salvage high-dose chemotherapy (sHDCT; melphalan 200 mg/m2), autologous stem cell transplantation (ASCT), and LEN maintenance (10 mg/d; transplant
-
Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors Blood (IF 21.0) Pub Date : 2025-01-16 Constantine S. Tam, Shalini Balendran, Piers Blombery
Bruton tyrosine kinase inhibitors (BTKis) are an established standard of care in chronic lymphocytic leukemia. The covalent BTKis ibrutinib, acalabrutinib, and zanubrutinib bind to BTK C481 and are all susceptible to the C481S mutation. Noncovalent BTKi, including pirtobrutinib, overcome C481S resistance but are associated with multiple variant (non-C481) BTK mutations, including those associated with